GENES, CALCIUM AND MODIFYING FACTORS IN HYPERTROPHIC CARDIOMYOPATHY

1 Familial hypertrophic cardiomyopathy (FHC) is a primary disorder of the myocardium characterized by remarkable diversity in clinical presentations, ranging from no symptoms to severe heart failure and sudden cardiac death. 2 Over the past 15 years, at least 11 genes have been identified, defects of which cause FHC. Most of these genes encode proteins that comprise the basic contractile unit of the heart (i.e. the sarcomere). 3 Genetic studies are now beginning to have a major impact on the diagnosis in FHC, as well as in guiding treatment and preventative strategies. Although much is known about which genes cause disease, relatively little is known about the molecular steps leading from the gene defect to the clinical phenotype and what factors modify the expression of the mutant genes. 4 Concurrent studies in cell culture and animal models of FHC are now beginning to shed light on the signalling pathways involved in FHC and the role of both environmental and genetic modifying factors. Calcium dysregulation appears to be important in the pathogenesis of FHC. 5 Understanding these basic molecular mechanisms will ultimately improve our knowledge of the basic biology of heart muscle function and will therefore provide new avenues for diagnosis and treatment not only for FHC, but also for a range of human cardiovascular diseases.

[1]  F O Mueller,et al.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.

[2]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[3]  A. Marian Modifier genes for hypertrophic cardiomyopathy. , 2002, Current opinion in cardiology.

[4]  F J Schoen,et al.  Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene. , 1999, The Journal of clinical investigation.

[5]  H. Schunkert,et al.  Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.

[6]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[7]  R. Liberthson,et al.  Sudden death from cardiac causes in children and young adults. , 1996, The New England journal of medicine.

[8]  A. Marian,et al.  Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. , 2004, Journal of the American College of Cardiology.

[9]  T. Hewett,et al.  Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[10]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[11]  T. Hewett,et al.  A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[12]  T. Ogihara,et al.  Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.

[13]  C. Semsarian,et al.  Hypertrophic cardiomyopathy: from "heart tumour" to a complex molecular genetic disorder. , 2004, Heart, lung & circulation.

[14]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[15]  J. Seidman,et al.  A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. , 2001, Journal of molecular and cellular cardiology.

[16]  Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study , 1996 .

[17]  T. Hewett,et al.  A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[18]  J. Seidman,et al.  Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. , 1997, The Journal of clinical investigation.

[19]  G. Danieli,et al.  Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. , 2002, Journal of the American College of Cardiology.

[20]  C. Semsarian,et al.  Hypertrophic cardiomyopathy: from gene defect to clinical disease , 2003, Cell Research.

[21]  F J Schoen,et al.  Comparison of Two Murine Models of Familial Hypertrophic Cardiomyopathy , 2001, Circulation research.

[22]  A J Marian,et al.  A transgenic rabbit model for human hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[23]  L. Leinwand,et al.  Mice Expressing Mutant Myosin Heavy Chains Are a Model for Familial Hypertrophic Cardiomyopathy , 1996, Molecular medicine.

[24]  R C Elston,et al.  Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. , 2001, American journal of human genetics.

[25]  J. Schmitt,et al.  A Murine Model of Holt-Oram Syndrome Defines Roles of the T-Box Transcription Factor Tbx5 in Cardiogenesis and Disease , 2001, Cell.

[26]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[27]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[28]  A. Marks,et al.  Altered function and regulation of cardiac ryanodine receptors in cardiac disease. , 2003, Trends in biochemical sciences.

[29]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[30]  M. Entman,et al.  Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy , 2004, Circulation.

[31]  P. Elliott,et al.  Hypertrophic Cardiomyopathy: Histopathological Features of Sudden Death in Cardiac Troponin T Disease , 2001, Circulation.

[32]  D. Kass,et al.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. , 1999, The Journal of clinical investigation.

[33]  C. Semsarian,et al.  Causes of sudden cardiac death in young Australians , 2004, The Medical journal of Australia.

[34]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[35]  M. Entman,et al.  Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[36]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[37]  A. Wilde,et al.  Absence of Calsequestrin 2 Causes Severe Forms of Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation research.

[38]  M. Eldar,et al.  A missense mutation in the CASQ2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia. , 2003, Trends in cardiovascular medicine.

[39]  L. Tiret,et al.  Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. , 1996, The New England journal of medicine.

[40]  J. Seidman,et al.  Ventricular Arrhythmia Vulnerability in Cardiomyopathic Mice With Homozygous Mutant Myosin-Binding Protein C Gene , 2001, Circulation.

[41]  D. Levy,et al.  Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. , 1996, The New England journal of medicine.

[42]  S. Priori,et al.  Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia , 2001, Circulation.

[43]  C. Semsarian,et al.  Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy. , 2004, International journal of cardiology.